BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tateo V, Manuzzi L, Parisi C, De Giglio A, Campana D, Pantaleo MA, Lamberti G. An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. Pharmaceuticals (Basel) 2021;14:316. [PMID: 33915954 DOI: 10.3390/ph14040316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Montella L, Ottaviano M, Morra R, Pietroluongo E, De Placido P, Tortora M, Sorrentino C, Facchini G, De Placido S, Giuliano M, Palmieri G. The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? Cancers (Basel) 2022;14:774. [PMID: 35159040 DOI: 10.3390/cancers14030774] [Reference Citation Analysis]
2 Szpechcinski A, Szolkowska M, Winiarski S, Lechowicz U, Wisniewski P, Knetki-wroblewska M. Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas. Cancers 2022;14:3388. [DOI: 10.3390/cancers14143388] [Reference Citation Analysis]
3 Nakamura S, Tateyama H, Nakanishi K, Sugiyama T, Kadomatsu Y, Ueno H, Goto M, Ozeki N, Fukui T, Yokoi K, Chen-Yoshikawa TF. Pleural Invasion Depth of Disseminated Nodules in Patients with Stage IVa or Recurrent Thymoma: Assessment, Curative Impact, and Surgical Outcomes. Ann Surg Oncol 2021. [PMID: 34657225 DOI: 10.1245/s10434-021-10888-0] [Reference Citation Analysis]
4 Muto Y, Okuma Y. Therapeutic options in thymomas and thymic carcinomas. Expert Rev Anticancer Ther 2022. [PMID: 35266421 DOI: 10.1080/14737140.2022.2052278] [Reference Citation Analysis]